公开(公告)号：WO2023089132A1

公开(公告)日：2023-05-25

申请号：PCT/EP2022/082486

申请日：2022-11-18

申请人： SMALL PHARMA LTD

发明人： RANDS, Peter ,  ROUTLEDGE, Carol ,  LAYZELL, Marie ,  JAMES, Ellen ,  JOEL, Zelah ,  BENWAY, Tiffanie ,  GOOD, Meghan

IPC分类号： A61K31/4045 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/12 ,  A61K45/06 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/30

摘要： The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, preferably from about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent. These formulations can comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less. Such formulations are surprisingly suitable both for intramuscular injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

公开(公告)号：WO2023083978A1

公开(公告)日：2023-05-19

申请号：PCT/EP2022/081517

申请日：2022-11-10

申请人： UMECRINE AB

发明人： BÄCKSTRÖM, Torbjörn ,  RAGAGNIN, Gianna ,  SJÖSTEDT, Jessica

IPC分类号： C07J41/00 ,  A61P3/04 ,  A61P3/10 ,  A61P15/00 ,  A61P25/30 ,  A61P25/32 ,  A61K31/568 ,  C07J1/00

摘要： The present disclosure concerns the novel compound 3. alpha.- ethynyl-3. beta.-hydroxy-5. alpha.-androstan-17-methoxime, the medical use thereof and in particular use in the treatment of diseases and disorders associated with an a3 subtype of the GABAA receptor, for example treatment of obesity, hyperphagia disorder, Prader- Willi's syndrome, polycystic ovarian syndrome, and/or diabetes. Said disclosure is also concerned with reducing and/or preventing overweight. Additionally, related pharmaceutical and cosmetic compositions are disclosed.

公开(公告)号：WO2023048152A1

公开(公告)日：2023-03-30

申请号：PCT/JP2022/035044

申请日：2022-09-21

申请人： 塩野義製薬株式会社

发明人： 上野　達彦 ,  安井　里奈

IPC分类号： C07D471/10 ,  A61K31/438 ,  A61K31/444 ,  A61K31/506 ,  A61K31/527 ,  A61P15/10 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D498/10

摘要： 本発明は、セロトニン５－ＨＴ２Ａ受容体拮抗および／もしくは逆作動作用を有する化合物またはその製薬上許容される塩ならびにそれらを含有する医薬組成物を提供する。 式（Ｉ）（式中、Ｒ１は水素原子等であり、Ａ１はそれぞれ独立してＣＲ２Ｒ２'であり、Ａ２はそれぞれ独立してＣＲ３Ｒ３'であり、Ｒ２はそれぞれ独立して水素原子等であり、Ｒ２' はそれぞれ独立して水素原子等であり、Ｒ３はそれぞれ独立して水素原子等であり、Ｒ３'はそれぞれ独立して水素原子等であり、ｍおよびｎはそれぞれ独立して１等であり、環Ｂは式（ＩＩ）等（式中、Ｒ４は式（ＩＩＩ）等（式中、Ａ３はそれぞれ独立してＣＲ１３Ｒ１３'であり、Ａ４はそれぞれ独立してＣＲ１４Ｒ１４'であり、Ｒ１３はそれぞれ独立して水素原子等であり、Ｒ１３'はそれぞれ独立して水素原子等であり、Ｒ１４はそれぞれ独立して水素原子等であり、Ｒ１４'はそれぞれ独立して水素原子等であり、ｑおよびｒはそれぞれ独立して１等であり、Ｒ１０およびＲ１１はそれぞれ独立して、置換もしくは非置換の芳香族炭素環式基等である）で示される基であり、Ｒ８は水素原子等である）で示される環である）で示される化合物またはその製薬上許容される塩。

公开(公告)号：WO2023028518A2

公开(公告)日：2023-03-02

申请号：PCT/US2022/075391

申请日：2022-08-24

申请人： UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

发明人： ZHAN, Chang-Guo ,  ZHENG, Fang

IPC分类号： A61K38/17 ,  A61P3/04 ,  A61P25/30 ,  C12N9/18 ,  A61K38/48

摘要： Compositions and methods for converting ghrelin to desacyl-ghrelin include a butyrylcholinesterase (BChE) polypeptide variant. The presently-disclosed subject matter includes compositions and methods for use in directly downregulating ghrelin. In particular, certain embodiments relate to compositions and methods for hydrolyzing/deacylating ghrelin to desacyl-ghrelin and applications thereof in the treatment of disorders involving ghrelin.

公开(公告)号：WO2023009584A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/038459

申请日：2022-07-27

申请人： SAGE THERAPEUTICS, INC.

发明人： KUANG, Shanming ,  LI, Tianrui

IPC分类号： C07J43/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/08 ,  A61P25/14 ,  A61P25/18 ,  A61P25/28 ,  A61P25/30 ,  A61K31/58

摘要： This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.

公开(公告)号：WO2023283392A1

公开(公告)日：2023-01-12

申请号：PCT/US2022/036437

申请日：2022-07-08

申请人： GILA THERAPEUTICS, INC.

发明人： VASICEK, Thomas

IPC分类号： A61K38/00 ,  A61P25/30

摘要： The invention provides compositions and methods for inducing activating a neural receptor. The compositions include a metabolic hormone, which can be used to provide treatment for an addiction or mood disorder in a subject.

公开(公告)号：WO2023280550A1

公开(公告)日：2023-01-12

申请号：PCT/EP2022/066615

申请日：2022-06-17

申请人： AXOLTIS PHARMA

发明人： LEMARCHANT, Sighild, Brunhilde, Adeline ,  GODFRIN, Yann ,  SOURIOUX, Mélissa, Christine

IPC分类号： A61K38/17 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  A61K38/1709

摘要： The invention relates to polypeptides derived from SCO-spondin for increasing or enhancing the basal excitatory synaptic transmission, notably glutamatergic neurotransmission. More particularly the invention relates to said polypeptides for increasing or enhancing glutamatergic neurotransmission in diseases or conditions comprising psychiatric disorders; drug addiction; viral infection (such as coronaviruses, e.g. SARS CoV2) related neurological symptoms; NMDA receptor (NMDAr) and/or AMPA receptor (AMPAr) deficiency related disease, notably anti-NMDAr encephalitis; vegetative state, and hypoxic brain injury. The present invention also relates to methods of treatment.

公开(公告)号：WO2023278108A1

公开(公告)日：2023-01-05

申请号：PCT/US2022/032601

申请日：2022-06-08

申请人： MIND MEDICINE, INC.

发明人： BARROW, Robert ,  KARLIN, Daniel R.

IPC分类号： A61K31/33 ,  A61K31/41 ,  A61K31/433 ,  A61K31/00 ,  A61K31/55 ,  A61P25/30 ,  A61P3/04

摘要： A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction.

公开(公告)号：WO2022167685A1

公开(公告)日：2022-08-11

申请号：PCT/EP2022/053013

申请日：2022-02-08

申请人： ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  UNIVERSITE DE PARIS

发明人： HOERTEL, Nicolas ,  LIMOSIN, Frédéric ,  SANCHEZ RICO, Marina Lucia

IPC分类号： A61K31/5513 ,  A61P25/00 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/30

摘要： The present invention is based on the finding that Benzodiazepine Receptor Agonists (BZRA), including benzodiazepines and Z-drugs, are significantly associated with increased mortality among patients hospitalized for COVID-19, with a significant dose-dependent relationship. It is therefore suggested to decrease the dose or to taper off these medications, when possible, in these patients. Importantly, this lethal association was not observed for only one BZRA, namely diazepam. This knowledge will help guide clinicians on the choice of the molecule to prescribe to patients with COVID-19 with clinical indication of a BZRA treatment (e.g. patients with benzodiazepine use disorder, delirium tremens, epilepsy, alcohol withdrawal symptoms, etc…).

公开(公告)号：WO2022160987A1

公开(公告)日：2022-08-04

申请号：PCT/CN2021/138062

申请日：2021-12-14

申请人： 中国科学院深圳先进技术研究院

发明人： 严飞 ,  谢丽婷

IPC分类号： A61K49/22 ,  A61K47/68 ,  A61K47/55 ,  A61P25/00 ,  A61P25/14 ,  A61P25/08 ,  A61P25/16 ,  A61P25/24 ,  A61P25/30 ,  A61P25/20

摘要： 一种离子通道靶向微泡及其制备方法和应用，其包括壳膜和生物惰性气体，生物惰性气体封于壳膜围合形成的囊体内，壳膜外表面结合有离子通道抗体。该离子通道靶向微泡通过离子通道抗体与离子通道靶向结合，可增强超声神经刺激响应的灵敏度。